In the present study, in contrast to previous PD research focusing on non-SUMO modifications or specific sites, we identified SUMO3 and SEH1L—both associated with SUMOylation—as potential novel biomarkers for PD. This evidence concerns the gene SEH1L and Parkinson disease.